Revvity launches AI-powered multimodal analysis software for imaging research

Published 29/09/2025, 13:22
Revvity launches AI-powered multimodal analysis software for imaging research

WALTHAM, Mass. - Revvity, Inc. (NYSE:RVTY), a $9.76 billion life sciences company with impressive fundamentals including a perfect Piotroski Score of 9, announced Monday the release of its Living Image Synergy AI multimodal analysis software designed for in vivo imaging researchers. The new platform unifies data analysis across optical, microCT, ultrasound, and other imaging modalities.

The software aims to reduce data inconsistencies, streamline workflows, increase throughput, and enhance reproducibility in preclinical imaging research. It centralizes analysis functions that previously required separate tools, allowing researchers to correlate datasets from different imaging technologies. According to InvestingPro analysis, Revvity maintains strong operational efficiency with a gross profit margin of 55.92% and a healthy current ratio of 3.33, indicating solid financial backing for its R&D initiatives.

"Our Living Image Synergy AI software marks a significant leap forward in preclinical imaging analysis," said Kevin Quick, VP of platforms at Revvity. "By unifying disparate analysis tools and integrating AI into existing workflows, Revvity’s new solution is directed towards enabling earlier insights and more consistent analysis across modalities."

The platform incorporates AI algorithms that automate image segmentation and region-of-interest quantification, tasks that have traditionally been labor-intensive and subject to variability. These features are designed to support high-throughput analysis and more efficient monitoring of disease progression and therapeutic efficacy.

Revvity will showcase the Living Image Synergy AI software at the WMIC conference in Anchorage, Alaska, taking place from Monday through October 3.

The company, which reported 2024 revenue of more than $2.7 billion and employs approximately 11,000 people, serves customers across pharmaceutical and biotech industries, diagnostic labs, academia, and governments in over 160 countries. Revvity is listed on the S&P 500 index.

This information is based on a press release statement from Revvity.

In other recent news, Revvity Inc has been the subject of multiple analyst revisions following its second-quarter earnings report. The company reported organic growth of 3%, aligning with consensus estimates, and earnings per share of $1.18, surpassing analyst expectations of $1.14 by 3.5%. Despite these results, several firms have adjusted their price targets for Revvity, citing challenges in the Chinese market as a significant factor. Stifel lowered its price target to $110 while maintaining a Hold rating, noting pressures in the China ImmunoDx sector. Raymond James also reduced its price target to $115, attributing the change to reimbursement headwinds in China affecting multiplex immunodiagnostics. Bernstein SocGen Group followed suit, setting their target at $115, while Jefferies decreased its target to $100 due to guidance adjustments related to China’s drug-related group policies. KeyBanc, however, reiterated its Overweight rating with a price target of $125, despite lowering estimates based on management’s comments about future operating margins and growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.